Good Life Advisors LLC Has $1.42 Million Stake in Bristol-Myers Squibb Co (NYSE:BMY)

Good Life Advisors LLC grew its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 6.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,120 shares of the biopharmaceutical company’s stock after purchasing an additional 1,348 shares during the period. Good Life Advisors LLC’s holdings in Bristol-Myers Squibb were worth $1,423,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of BMY. Nuveen Asset Management LLC boosted its position in shares of Bristol-Myers Squibb by 14,860.1% during the 2nd quarter. Nuveen Asset Management LLC now owns 9,395,120 shares of the biopharmaceutical company’s stock valued at $426,069,000 after acquiring an additional 9,332,319 shares in the last quarter. BlackRock Inc. boosted its position in shares of Bristol-Myers Squibb by 6.7% during the 2nd quarter. BlackRock Inc. now owns 114,798,394 shares of the biopharmaceutical company’s stock valued at $5,206,108,000 after acquiring an additional 7,178,698 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Bristol-Myers Squibb by 42.7% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 12,749,545 shares of the biopharmaceutical company’s stock valued at $578,192,000 after acquiring an additional 3,816,247 shares in the last quarter. Eaton Vance Management boosted its position in shares of Bristol-Myers Squibb by 108.3% during the 2nd quarter. Eaton Vance Management now owns 5,195,648 shares of the biopharmaceutical company’s stock valued at $235,623,000 after acquiring an additional 2,701,008 shares in the last quarter. Finally, Prudential PLC boosted its position in shares of Bristol-Myers Squibb by 438.6% during the 2nd quarter. Prudential PLC now owns 2,907,501 shares of the biopharmaceutical company’s stock valued at $130,846,000 after acquiring an additional 2,367,644 shares in the last quarter. Institutional investors own 83.02% of the company’s stock.

In other Bristol-Myers Squibb news, insider Louis S. Schmukler sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $56.56, for a total value of $1,414,000.00. Following the completion of the transaction, the insider now directly owns 31,963 shares of the company’s stock, valued at $1,807,827.28. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP John E. Elicker sold 15,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total transaction of $849,900.00. Following the completion of the transaction, the senior vice president now directly owns 74,471 shares of the company’s stock, valued at $4,219,526.86. The disclosure for this sale can be found here. Company insiders own 0.13% of the company’s stock.

BMY has been the topic of several recent research reports. Bank of America initiated coverage on shares of Bristol-Myers Squibb in a research report on Wednesday, October 16th. They set a “buy” rating and a $60.00 target price on the stock. Gabelli initiated coverage on shares of Bristol-Myers Squibb in a research report on Wednesday, November 27th. They set a “buy” rating on the stock. Morgan Stanley initiated coverage on shares of Bristol-Myers Squibb in a research report on Friday, November 22nd. They set an “equal weight” rating and a $60.00 target price on the stock. UBS Group lifted their target price on shares of Bristol-Myers Squibb from $51.00 to $53.00 and gave the company a “neutral” rating in a research report on Wednesday, October 23rd. Finally, William Blair reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research report on Friday, December 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Buy” and a consensus price target of $61.69.

BMY stock traded up $0.32 during trading on Friday, hitting $67.10. 2,302,720 shares of the stock traded hands, compared to its average volume of 15,257,604. Bristol-Myers Squibb Co has a one year low of $42.48 and a one year high of $67.09. The stock has a market cap of $108.25 billion, a price-to-earnings ratio of 16.86, a P/E/G ratio of 0.85 and a beta of 0.73. The company has a 50 day simple moving average of $62.71 and a 200 day simple moving average of $53.14. The company has a current ratio of 3.83, a quick ratio of 3.72 and a debt-to-equity ratio of 1.37.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. The firm had revenue of $6.01 billion during the quarter, compared to the consensus estimate of $5.89 billion. During the same period last year, the firm posted $1.09 EPS. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. As a group, analysts predict that Bristol-Myers Squibb Co will post 4.47 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be issued a dividend of $0.45 per share. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. This represents a $1.80 annualized dividend and a yield of 2.68%. The ex-dividend date of this dividend is Thursday, January 2nd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 45.23%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Story: What member countries make up the G-20?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.